PANDEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PANDEL (PANDEL).
Pandel (hydrocortisone probutate) is a topical corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. These proteins inhibit the release of arachidonic acid from membrane phospholipids, thereby reducing the synthesis of prostaglandins, leukotrienes, and other inflammatory mediators. This results in vasoconstriction, decreased edema, and suppression of the inflammatory and pruritic responses.
| Metabolism | Hydrocortisone probutate is metabolized primarily in the skin and liver via ester hydrolysis to inactive metabolites. |
| Excretion | Primarily renal (90% as unchanged drug); biliary/fecal excretion negligible (<5%). |
| Half-life | 2-4 hours (terminal); clinical context: requires frequent dosing due to rapid elimination. |
| Protein binding | 20-30% bound to albumin; low binding minimizes drug interactions. |
| Volume of Distribution | 0.3-0.5 L/kg; indicates distribution primarily into extracellular fluid. |
| Bioavailability | Oral: 70-90% (high, with minimal first-pass effect); Intravenous: 100%. |
| Onset of Action | Intravenous: 5-10 minutes; Oral: 30-60 minutes. |
| Duration of Action | Intravenous: 4-6 hours; Oral: 6-8 hours (dose-dependent). |
Topical: Apply a thin film to affected skin areas twice daily. Maximum: 15 g per application; not to exceed 60 g per week.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for topical use; systemic absorption is minimal. |
| Liver impairment | No dosage adjustment required for topical use; systemic absorption is minimal. |
| Pediatric use | Children (≥12 years): Same as adult. Children (2-11 years): Apply a thin film to affected area once daily. Maximum: 7.5 g per application; not to exceed 30 g per week. |
| Geriatric use | No specific dose adjustment; use caution due to increased risk of skin atrophy and systemic absorption with prolonged use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PANDEL (PANDEL).
| Breastfeeding | Excretion into breast milk is unlikely with topical application; however, use lowest potency for shortest duration. Avoid application to breast area to prevent infant ingestion. M/P ratio not established. |
| Teratogenic Risk | Insufficient human data; animal studies not available. Based on drug class (topical corticosteroid), systemic absorption is minimal with short-term use on limited areas. Avoid prolonged use on large areas, occluded skin, or in first trimester due to theoretical risk of orofacial clefts (1st trimester) and intrauterine growth restriction or adrenal suppression (2nd/3rd trimester) with high-potency agents. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to hydrocortisone probutate or any component of the formulation.","Untreated bacterial, fungal, or viral skin lesions (e.g., herpes simplex, varicella, tuberculosis).","Perioral dermatitis, rosacea, acne vulgaris."]
| Precautions | ["Topical use only; not for ophthalmic, oral, or intravaginal use.","Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria, especially with prolonged use, large surface area application, occlusive dressings, or in pediatric patients.","Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-mass ratio.","Local adverse reactions include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, maceration, and miliaria.","May mask signs of infection; use caution in the presence of infection and discontinue if infection develops.","Prolonged use may lead to development of tolerance or tachyphylaxis."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of maternal systemic absorption (hyperglycemia, hypertension, electrolyte imbalances) if used extensively. Fetal monitoring: ultrasound for growth restriction if high-dose or prolonged use. |
| Fertility Effects | No known effects on fertility in humans; animal studies with systemic corticosteroids showed impaired fertility at high doses. |